Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 4/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407032 | 0.76 | APLNR (0.43) | APLNRTDP1MAPK1CA1CA2 | |
| SCHEMBL27891717 | 0.74 | APLNR (0.42) | APLNRTDP1MAPK1CA1CA2 | |
| SCHEMBL17707949 | 0.73 | APLNR (0.40) | APLNRALOX5TDP1ALDH1A1CA1 | |
| SCHEMBL5073789 | 0.71 | APLNR (0.44) | APLNRTDP1MAPK1CA1CA2 | |
| SCHEMBL17708251 | 0.70 | APLNR (0.40) | APLNRALOX5TDP1CA1CA2 | |
| SCHEMBL284141 | 0.70 | APLNR (0.55) | APLNRTDP1ALDH1A1MAPK1CA1 | |
| SCHEMBL18420350 | 0.69 | TDP1 (0.53) | TDP1ALDH1A1CA1CA2CA7 | |
| SCHEMBL6073669 | 0.68 | CYP2D6 (0.33) | APLNRTDP1ALDH1A1CA1CA2 | |
| SCHEMBL10068419 | 0.68 | CA1 (0.46) | CA1CA2CA7MEN1KMT2A | |
| SCHEMBL7643226 | 0.67 | MEN1 (0.41) | APLNRTDP1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590982-B1 | PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT | THE WALTER AND ELIZA HALL INST OF MEDICAL RES (AU) | 2017-08-23 | — | — | EP | disclosed |
| EP-2590982-B1 | PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT | THE WALTER AND ELIZA HALL INST OF MEDICAL RES (AU) | 2017-08-23 | — | — | EP | disclosed |
| US-8962830-B2 | Protein kinase inhibitors and methods of treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2015-02-24 | — | — | US | disclosed |
| US-8962830-B2 | Protein kinase inhibitors and methods of treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2015-02-24 | — | — | US | disclosed |
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-18 | — | — | US | disclosed |
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-07-18 | — | — | US | disclosed |
| EP-2590982-A1 | PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT | The Walter and Eliza Hall Institute of Medical Research (AU) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012003544-A1 | PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012003544-A1 | PROTEIN KINASE INHIBITORS AND METHODS OF TREATMENT | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184274-A1 | Protein Kinase Inhibitors and Methods of Treatment | PRKDC, PRKACA, PRKX | APLNR 4192/4885ALOX5 2507/4885TDP1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.